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Background: New biomarkers are needed for the prognosis of advanced colorectal cancer, which remains
incurable by conventional treatments. O6-methylguanine DNA methyltransferase (MGMT) methylation and protein
expression have been related to colorectal cancer treatment failure and tumor progression. Moreover, the presence
in these tumors of cancer stem cells, which are characterized by CD133 expression, has been associated with
chemoresistance, radioresistance, metastasis, and local recurrence. The objective of this study was to determine the
prognostic value of CD133 and MGMT and their possible interaction in colorectal cancer patients.
Methods: MGMT and CD133 expression was analyzed by immunohistochemistry in 123 paraffin-embedded colorectal
adenocarcinoma samples, obtaining the percentage staining and intensity. MGMT promoter methylation status was
obtained by using bisulfite modification and methylation-specific PCR (MSP). These values were correlated with clinical
data, including overall survival (OS), disease-free survival (DFS), tumor stage, and differentiation grade.
Results: Low MGMT expression intensity was significantly correlated with shorter OS and was a prognostic factor
independently of treatment and histopathological variables. High percentage of CD133 expression was significantly
correlated with shorter DFS but was not an independent factor. Patients with low-intensity MGMT expression
and ≥50% CD133 expression had the poorest DFS and OS outcomes.
Conclusions: Our results support the hypothesis that MGMT expression may be an OS biomarker as useful as tumor
stage or differentiation grade and that CD133 expression may be a predictive biomarker of DFS. Thus, MGMT and
CD133 may both be useful for determining the prognosis of colorectal cancer patients and to identify those requiring
more aggressive adjuvant therapies. Future studies will be necessary to determine its clinical utility.
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According to the World Health Organization (WHO),
colorectal cancer (CRC) is the third most common can-
cer in males and the second in females and is the fourth
cause of cancer death. The WHO expects an increase in
CRC incidence and mortality, with estimates of around
1,471,808 newly diagnosed patients and 726,028 deaths
worldwide in 2015 [1]. Almost all (95%) of these new* Correspondence: melguizo@ugr.es
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unless otherwise stated.CRCs are likely to be adenocarcinomas and, despite re-
cent advances in detection and therapy, 25% of these pa-
tients will develop metastasis and have a very low 5-year
survival rate of around 10% [2,3]. New biomarkers of
CRC are needed to permit an earlier diagnosis and to
predict the response to treatment.
Screening for the early detection of CRC is the most
effective approach against this disease [4]. Carcinoem-
bryonic antigen (CEA) is recommended as a biomarker
to detect spread of the cancer and to follow up CRC pa-
tients. However, in the diagnosis of early CRC it has
major limitations such as low sensitivity and specificity
(36% and 87% respectively). In addition, until a rate oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as O6-methylguanine-DNA methyltransferase (MGMT)
and CD133 have been proposed as useful tools for the
diagnosis, prognosis, and follow-up of CRC and for the
detection of relapse [7]. MGMT is a DNA repair protein
that removes O6-guanine adducts from DNA [8]. MGMT
restores mutagenic O6-methylguanine to guanine in nor-
mal colonic tissue, preventing DNA alkylation damage [9].
MGMT hypermethylation in CpG islands and low
MGMT protein expression appear to be early events in
CRC patients. This MGMT epigenetic silencing may lead
to G:C to A:T transition mutations in p53 [10], K-ras
[11-13], PIK3CA [11,14], and hMLH1 [15], among others.
Furthermore, CD133, a transmembrane glycoprotein re-
lated to cell-cell interaction and signal transduction, has
been associated with cancer stem cells (CSCs), including
those in CRC [16]. This CSC subpopulation represents a
small number of tumor cells that can self-renew indefin-
itely and recreate parent tumor cells expressing different
surface biomarkers [17]. This marker permits the hier-
archical organization of tumor heterogeneity, dividing
CRC cells between CD133-positive (CSCs) and CD133-
negative cells (non-CSCs) cells [18]. CD133-positive CRC
cells have shown special properties, including the capacity
to form tumors in xenografts [19], chemo- and radioresis-
tance [20,21], and metastasis promotion [22,23]. Previous
studies associated CSC chemo/radio-resistance to MGMT
expression in other cancers [24-26].
The aim of the present study was to analyze the clin-
ical implications of MGMT and CD133 in CRC and the
possible interactions between them in order to develop a
new prognostic biomarker for these patients. Immuno-
histochemical analysis of MGMT and CD133 expression
was carried out in colorectal cancer samples from 123
patients, and MGMT methylation status was determined
by methylation-specific PCR (MSP). The expression pat-
tern of the two molecules and MGMT methylation status
were correlated with overall survival (OS), disease-free
survival (DFS), tumor stage, and differentiation grade,
among others. MGMT expression intensity and percent-
age CD133 expression may be clinically useful for CRC
prognosis, but this does not appear to be the case for
MGMT methylation status or CD133 expression intensity.
Methods
Clinical tissue samples
In this cross-sectional study (case-series design), color-
rectal adenocarcinoma samples were obtained from pa-
tients at three hospitals in Southern Spain (Puerta del
Mar Hospital, Cádiz; Puerto Real Hospital, Cádiz; and
San Cecilio Hospital, Granada) between 2004 and 2009.
Clinical data of the patients were obtained from the hos-
pital records. Written informed consent was obtained
from all patients and controls before their enrolment inthe study. The study protocol was approved by the Bio-
medical Investigation Ethic Committee (Consejeria de
Salud; Servicio Andaluz de Salud). Paraffin-embedded
tumor specimens were obtained from 123 CRC patients.
The differentiation grade and tumor stage were deter-
mined according to standard histopathological criteria
by two expert pathologists [27]. DNA extraction and
analysis, MGMT methylation status test, tissue micro-
array (TMA) construction, and MGMT and CD133 im-
munohistochemical analyses were performed in samples
from each specimen. None of the patients had received
any pre-operative treatment. After the tumor resection,
most patients had been treated with chemotherapy (5-
fluorouracil [5-FU], oxaliplatin, and/or irinotecan) and/or
radiotherapy according to their clinical characteristics.
DNA extraction, bisulfite treatment, and
methylation-specific PCR
DNA was extracted from waxed tissue samples by using
the Chemagic MSM I robot (Chemagen, Germany,
Baesweiler) in accordance with the manufacturer’s stand-
ard recommendations. Determination of methylation
patterns in MGMT promoter CpG islands was based on
the chemical modification of unmethylated (but not
methylated) cytosine to uracil. MSP was performed with
specific primers for either methylated or unmethylated
DNA, as previously described [10]. Briefly, a 2-μg DNA
sample was denatured with sodium hydroxide, modified
with sodium bisulfite, and then purified (EpiTect Bisulfite
kit, Qiagen, USA, Maryland). Primer sequences were 5′-
TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3′ (for-
ward primer) and 5′-AACTCCACACTCTTCCAAAAAC
AAAACA-3′ (reverse primer) for the unmethylated (UM)
reaction and were 5′-TTTCGACGTTCTAGGTTTTC
GC-3′ (forward primer) and 5′-GCACTCTTCCGAAAA
CGAAACG-3′ (reverse primer) for the methylated (M)
reaction. PCR-amplified products were electrophoresed
on 3% agarose gels, visualized by staining with ethidium
bromide, and examined under UV illumination. A sample
was classified as hypermethylated when the methylation
amplification product alone was observed, partially meth-
ylated when both methylated and unmethylated amplifica-
tion products were seen, and unmethylated when it
showed unmethylated amplification products alone. For
the statistical analysis, the hypermethylated and partially
methylated samples were considered as the methylated
(M) group and compared with the unmethylated (UM)
group.
Immunohistochemistry
Formalin-fixed paraffin-embedded CRC tumor samples
were used in the construction of TMAs. Briefly, four rep-
resentative areas were selected from whole hematoxylin-
eosin tissue sections of each adenocarcinoma specimen.
Table 1 Clinical characteristics of colon adenocarcinoma
patients
Feature Classification n (%)
Sex Male 80 (65)
Female 43 (35)
Age ≥50 years 116 (94.3)
<50 years 7 (5.7)
Tumor differentiation
grade
Well differentiated 37 (31.6)
Moderately differentiated 59 (50.4)
Poorly differentiated 21 (17.9)




Radiotherapy treatment Did not receive radiotherapy 96 (87.3)
Received radiotherapy 14 (12.7)
Chemotherapy
treatment
Did not receive chemotherapy 47 (38.8)




Some treatment 70 (63.6)
Treatment response Response 61 (58.1)
No response 44 (41.9)
Last follow-up status Alive without disease 66 (65.3)
Alive with disease 17 (16.8)
Disease progression and death 18 (17.8)
Sample size for sex and age (n = 123), for tumor differentiation grade (n = 117),
for tumor stage (n = 122), for radiotherapy treatment (n = 110), for chemotherapy
treatment (n = 121), for a treatment (n = 110), for treatment response (n = 105)
and last follow-up status (n = 101).
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in a grid layout using a Manual Tissue Microarrayer
(Beecher Instruments, Silver Spring, MD). The resulting
tissue microarray blocks were cut into 5-μm sections with
a microtome, placed on slides by the adhesive tape-
transfer method (Instrumedics, Inc., Hackensack, NJ), and
UV cross-linked. TMA dewaxing, rehydration, epitope re-
covery, and all staining procedures were performed at the
same time with the DakoAutostainer EnVision™ FLEX kit
(Dako, Barcelona, Spain) using antibodies against MGMT
(1:50, Santa Cruz Biotechnology, Inc., Heidelberg, Germany)
and CD133 (1:50, Miltenyi Biotec, Bergisch Gladbach,
Germany). The antibodies were incubated with 3.3′-di-
aminobenzidine (DAB) substrate-chromogen, resulting in
a brown-colored precipitate at the antigen site, and cell
nuclei were visualized with hematoxylin (blue) counter-
staining; nerve tissue was used as a positive control [28].
The readings were done by two experienced pathologists
under light microscopy. In the most of specimens, there
weren’t significant differences between observers and sam-
ple punches. Furthermore, the patients with heteroge-
neous staining for any antibody were not included in this
study. The MGMT staining of tumor cells was scored and
grouped as low expression (<50%) (−, +, and ++ scores)
and high expression (≥50%) (+++ and ++++ scores).
CD133 staining of tumor glands was classified as 0%, <50%,
or ≥50%; CD133 staining on the apical and/or endolum-
inal surface of tumor glands and/or on cell debris was
considered positive, in accordance with previous studies
[29]. For the statistical analysis, CD133 expression was
considered in two categories: low (<50%) or high (≥50%).
The intensity of MGMT and CD133 staining was scored
as low or high. Thereby, percentage only consider number
of cells or tumor glands stained for MGMT and CD133
independently to dye distribution; moreover, intensity was
scored high when nucleus or tumor glands were com-
pletely stained and low when showed partially or lack of
staining regardless of number of cells or tumor glands
stained.
Statistical analysis
Contingency tables and associations were analyzed with
the chi-square (χ2) test and Fisher’s exact test. DFS (time
elapsed between diagnosis and disease recurrence) and
OS (time between diagnosis and death) curves were esti-
mated with the Kaplan-Meier method. A two-sided log-
rank test was used to determine significant differences
between independent curves and patient groups. Signifi-
cant prognostic factors associated with DFS and/or OS
were identified by applying the Cox proportional hazards
model, which was constructed using the most relevant
molecular, histopathological, and treatment variables.
SPSS version 15.0 was used for the data analyses; p < 0.05
was considered significant.Results
Patient characteristics
Table 1 summarizes the characteristics of the 123 pa-
tients in the study (65% males, 35% females); the mean
(± standard deviation) age was 71.73 ± 10.57 yrs (range,
40 to 93 yrs). The tumor was in stage III in 40.2% (49/
122) of patients and the differentiation grade was mod-
erate in 50.4% (59/117). At the most recent follow up,
17.8% (18/101) of the patients had died due to the colo-
rectal adenocarcinoma and 41.9% (44/105) of the pa-
tients did not respond to treatment, evidencing local or
distal recurrence. The follow-up period ranged between
2 and 93 months. The mean OS of the whole sample
was 40.20 ± 22.09 months and the mean DFS was 35.98 ±
24.75 months.
MGMT promoter methylation status and MGMT expression
Table 2 summarizes the molecular characteristics of the
patients. MGMT promoter methylation status could be
Table 2 Molecular characteristics of colon adenocarcinoma
patients
Feature Classification n (%)
MGMT methylation status Unmethylated 24 (21.8)
Methylated 86 (78.2)
Percentage MGMT expression Low 55 (48.2)
High 59 (51.8)
MGMT expression intensity Low 30 (26.3)
High 84 (73.7)
Percentage CD133 expression Low 52 (47.3)
High 58 (52.7)
CD133 expression intensity Low 70 (63.6)
High 40 (36.4)
Sample size for MGMT methylation status (n = 110), for percentage MGMT
expression (n = 114), MGMT expression intensity (n = 114), percentage CD133
expression (n = 110), and CD133 expression intensity (n = 110).
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lification was unsuccessful or evaluation was not pos-
sible in the remaining 13 specimens. The M group
included 78.2% of the 110 cases and the UM group
21.8%. Out of the M group, 75.6% showed partial methy-
lation (amplification with UM and M primers) and
24.4% hypermethylation (amplification with M primer
alone) (Figure 1).Figure 1 Methylation-specific PCR analysis of the MGMT
promoter in colorectal adenocarcinoma tissue samples.
Representative image showing MGMT promoter methylation study
of 25 of the 110 analyzed patients. Partially-methylated patients
showed amplification of both UM and M lanes. Hypermethylated
patients showed only amplification of M lane. Unmethylated (UM)
patients showed lack of M lane.MGMT staining was always nuclear in colorectal adeno-
carcinoma gland cells and always detected in surrounding
tissue (Figure 2). Data on the percentage MGMT expres-
sion were available for 92.7% (114/123) of the patients.
Out of these 114 cases, no expression was observed in
15.8%, and expression was scored as + in 2.6%, ++ in
29.8%, +++ in 43.9%, and ++++ in 7.9% (Figure 2); hence,
low (<50%) MGMT expression was observed in 48.2% of
cases and high expression (≥50%) in 51.8%. No association
was found between percentage MGMT expression and
MGMT promoter methylation status (Additional file 1:
Table S1). A low intensity of MGMT expression was ob-
served in 26.3% of the 114 patients and a high intensity in
73.7% (Figure 2). A significant association was found
between low MGMT expression intensity and MGMT
promoter methylated (M) (Additional file 1: Table S1).
An association was observed between poor-tumor dif-
ferentiation grade and methylated MGMT promoter (M)
(Additional file 2: Table S2).
Influence of MGMT promoter methylation status and
MGMT protein expression on overall survival and
disease-free survival
The mean OS was 61.36 months in patients with low-
intensity MGMT expression versus 77.48 months in
those with high-intensity MGMT expression (Table 3);
the correlation between OS and MGMT expression in-
tensity was significant (p < 0.01) (Figure 3). MGMT ex-
pression intensity was a prognostic factor for OS after
adjusting for treatment and histopathology variables
(Table 4). No significant correlation was found between
OS and MGMT promoter methylation status or percent-
age MGMT expression (Table 3). No significant correl-
ation was observed between DFS and MGMT methylation
status, MGMT expression intensity, or percentage MGMT
expression (Table 3).
CD133 protein expression
CD133 expression results were available for 110 (89.4%) of
the patients (Table 2). CD133 expression was detected on
the endoluminal surface of tumor glands and on cell deb-
ris; no staining was observed in other tumor regions or in
normal tissues. Out of the 110 specimens analyzed, the
staining was scored as 0% in 12.7%, <50% in 34.6%,
and ≥50% in 52.7% (Figure 4). In addition, 36.4% of the
110 patients had a high-intensity CD133 expression and
63.6% a low-intensity expression (Figure 4). An association
was observed between no treatment response and high
CD133 percentage expression (Additional file 3: Table S3).
Influence of CD133 protein expression on overall survival
and disease-free survival
OS was not significantly associated with CD133 protein
expression intensity or percentage (Table 3). However, a
Figure 2 Immunohistochemical MGMT staining in colorectal adenocarcinoma tissue samples. (A) Representative photomicrographs of
TMA punches illustrating low (a) and high (b) MGMT expression intensity; bar, 50 μm. (B) Photomicrographs of TMA punches illustrating different
percentages MGMT expression levels: negative (a), <50% (b and c) and ≥50% (d and e); bar, 200 μm.
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between DFS and percentage CD133 expression (Figure 3),
with a mean DFS of 67.91 months in those with low
(<50%) expression versus 46.01 months in those with
higher (≥50%) CD133 expression (Table 3). The tumor
stage was also correlated with DFS (Table 3). The multi-
variable analysis results showed that CD133 protein ex-
pression was not an independent prognostic factor
(Table 4).
MGMT and CD133 interactions and clinical influence
No significant association was found between MGMT
promoter methylation or MGMT expression percentage/intensity and CD133 expression percentage/intensity
(Additional file 1: Table S1). CD133 expression percent-
age and MGMT intensity could be compared in 109 pa-
tients. Among the patients with low MGMT intensity,
CD133 expression percentage was low in 42.9% and high
in 57.1%. Among the patients with high MGMT inten-
sity, CD133 expression percentage was low in 48.1% and
high in 51.9%.
Study of the potential relationship of MGMT intensity
and percentage CD133 expression with clinical outcome
variables (Figure 3) revealed a significant correlation with
OS but no significant correlation with DFS (Table 3). The
patients with low-intensity MGMT expression and high
Table 3 Interaction of overall survival (OS) and disease-free survival (DFS) with histopathological variables
OS DFS
Variables Mean (95% CI) p value Mean (95% CI) p value
Sex Male 72.08 (62.61-81.55) 0.103 52.15 (42.12-62.18) 0.179
Female 79.52 (71.55-87.50) 61.00 (49.16-72.85)
Differentiation grade Well-moderate 77.62 (70.03-85.21) 0.408 56.25 (47.45-65.06) 0.649
Poor 64.14 (48.53-79.75) 56.50 (38.35-74.64)
Tumor stage I-II 80.75 (71.71-89.78) 0.167 70.31 (59.84-80.78) 0.002*
III-IV 68.89 (58.72-79.05) 42.44 (32.30-52.58)
MGMT methylation status Unmethylated 73.54 (65.17-81.90) 0.398 49.87 (34.54-65.20) 0.949
Methylated 76.07 (67.82-84.32) 57.33 (47.55-67.12)
Percentage MGMT expression Low 70.53 (60.02-81.05) 0.211 50.77 (39.35-62.20) 0.328
High 77.04 (69.58-84.50) 58.62 (48.37-68.87)
MGMT expression intensity Low 61.36 (45.99-76.72) 0.006* 47.76 (32.80-62.71) 0.171
High 77.48 (70.75-84.21) 56.43 (47.39-65.47)
Percentage CD133 expression Low 82.03 (72.97-91.10) 0.273 67.91 (56.68-79.14) 0.014*
High 70.41 (61.33-79.50) 46.01 (35.06-56.97)
CD133 expression intensity Low 77.90 (69.39-86.41) 0.642 59.76 (49.62-69.89) 0.517
High 78.00 (67.92-88.08) 53.74 (39.44-68.05)
High MGMT intensity CD133≥ 50% 73.06 (63.99-82.14) 0.032* 49.14 (36.25-62.04) 0.140
CD133 < 50% 72.33 (61.82-82.84) 57.08 (44.64-69.51)
Low MGMT intensity CD133≥ 50% 52.36 (30.53-74.19) 37.85 (18.87-56.83)
CD133 < 50% 69.50 (45.88-93.11) 64.50 (41.41-87.59)
Statistically significant variables (*p < 0.05). CI, confidence interval.
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and DFS (37.85 months) outcomes (Table 3).
Discussion
In this study of tumors from CRC patients, methylated
MGMT promoter was significantly associated with low
MGMT expression intensity and poor-differentiation
grade but not with OS, DFS, or tumor stage. High
MGMT expression intensity was correlated with longer
OS but not with DFS, tumor stage, or differentiation
grade. High percentage of CD133 expression was corre-
lated with shorter DFS but not with OS, tumor stage, or
differentiation grade. MGMT expression intensity can be
considered as an independent prognostic factor for OS,
but the influence of percentage CD133 expression on
the prognosis for DFS also depends on the tumor stage.
The relevance of MGMT in CRC carcinogenesis is
widely accepted, and reduced MGMT expression has
been documented in tumor versus normal colon tissue
[30]; however, the mechanism by which MGMT expres-
sion is controlled remains controversial. Lee et al. [31]
observed hypermethylated genes, including MGMT, in
early stages of colorectal adenoma, and MGMT promoter
methylation has been implicated in colon cancer progres-
sion (in the adenoma-carcinoma sequence) [31,32]. Sinhaet al. [33] demonstrated that MGMT promoter methyla-
tion was associated with tumor stage, metastasis, and
lymphatic invasion in advanced CRC. Various authors
have reported the effects of MGMT inactivation on other
cancer-related genes. It has been found that the epigenetic
silencing of MGMT by promoter hypermethylation can
lead to G:C to A:T transition mutations in p53 [10], K-ras
[11-13], and PIK3CA [11,14], facilitating progression of
the tumor to more advanced stages.
Based on the above data, research efforts have focused
on the diagnostic and prognostic relevance of MGMT.
Various authors have reported that MGMT methylation
is a useful marker to detect early stages of CRC [34,35].
Kang et al. [36] concluded that a more sensitive screen-
ing can be achieved by testing the DNA methylation sta-
tus of some genes, including MGMT, than by analyzing
fecal blood. In addition, Nagasaka et al. [37] and Nilsson
et al. [38] suggested that MGMT hypermethylation in
CRC may be related to non-recurrence after chemother-
apy and better survival. Experimental data support this
possibility, because 5-FU cytotoxicity was enhanced by
O6-benzylguanine-induced MGMT depletion in colon
cancer cells with high MGMT expression. It was suggested
that elevated MGMT levels may be a marker of a low
therapeutic response [39], and MGMT hypermethylation
Figure 3 Kaplan-Meier survival curves according to MGMT and/or CD133 expression in colorectal adenocarcinoma patients. (A) OS
curves for different MGMT expression intensity scores. (B) DFS curves for different percentage CD133 expression scores. (C) OS curves for different
MGMT and CD133 scores when analyzed together and (D) DFS curves for different MGMT and CD133 scores when analyzed together.
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[38]. In contrast, Shima et al. [11] found no significant
correlation between MGMT promoter status and survival
and suggested that this status has little clinical relevance.
Our results showed a significant association of methylated
MGMT promoter with low-MGMT expression intensity
and poor-differentiation grade. However, no correlation
was found between MGMT methylation and OS or DFS
in CRC patients, whereas high MGMT intensity was cor-
related with longer OS but not with tumor grade or differ-
entiation. These contradictory results may be related to
the multifactorial and complex regulation of MGMT pro-
tein expression. Two distinct patterns of MGMT methyla-
tion have been associated with different mutations orTable 4 Multivariate analysis: cox proportional hazards mode
OS
Variables HR (CI)
Sex (male/female) 2.69 (0.77-9.34)
Differentiation grade (well-moderate/poor) 0.62 (0.20-1.93)
Tumor grade (I-II/III-VI) 0.50 (0.18-1.35)
Radiotherapy (no/yes) 0.41 (0.13-1.27)
Chemotherapy (no/yes) 0.48 (0.16-1.49)
MGMT expression intensity (low/high) 3.73 (1.35-10.33)
Percentage CD133 expression (low/high) 0.54 (0.18-1.65)
HR, Hazard ratio. CI, confidence interval. Statistically significant variables (*p < 0.05).epigenetic changes in CRC [40], and methylation is not
the sole regulatory mechanism of MGMT protein levels
[41]. Some MGMT polymorphisms may reduce MGMT
activity and/or sensitivity [42,43] and have been associated
with progression-free survival in CRC patients [44]. Des-
pite MGMT hypermethylation or lack of MGMT protein
has been associated with a better treatment response and
survival at short-term [37-39], the epigenetic silencing of
MGMT promotes different mutations [10-14] which could
facilitate the tumor progression reducing the overall sur-
vival at long-term.
CD133 is widely recognized as a stem cell biomarker
in normal and cancer colon tissue [45-47]. Its expression
was detected in around half of a series of precancerousl for OS and DFS
DFS
p value HR (CI) p value
0.118 1.56 (0.80-3.05) 0.186
0.412 1.24 (0.48-3.17) 0.652
0.175 0.38 (0.19-0.73) 0.004*
0.123 0.64 (0.29-1.41) 0.276
0.210 0.50 (0.25-0.99) 0.049*
0.011* 1.55 (0.81-2.99) 0.182
0.280 0.44 (0.22-0.86) 0.018*
Figure 4 Immunohistochemical CD133 staining in colorectal adenocarcinoma tissue samples. (A) Representative photomicrographs of
TMA punches illustrating low (a) and high (b) CD133 expression intensity; bar, 50 μm. (B) Photomicrographs of TMA punches illustrating different
percentage CD133 expression levels: negative (a), <50% (b), ≥50% (c); bar, 200 μm.
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in invasive margins of colorectal tumors [29]. Other au-
thors reported that CD133 expression is not restricted
to intestinal stem or cancer-initiating cells and that both
CD133-positive and CD133-negative cells can initiate a
tumor [47]. In the present study, the high percentage of
CD133 expression was correlated with shorter DFS but
not with OS, tumor stage, or differentiation grade in
CRC patients, suggesting that this molecule may be rele-
vant to determine recurrence. These findings are con-
sistent with the study by Coco et al. [49], who found a
higher risk of recurrence and death in CRC patients with
increased CD133 levels. Reggiani et al. [50] concluded
that CD133 is useful for the prognosis in stage I CRC
patients and for the selection of patients requiring adju-
vant treatment. Moreover, Jao et al. [51] correlated cyto-
plasmic CD133 expression with tumor local recurrence
and survival in CRC patients. However, a similar study
found no correlation between cytoplasmic CD133 and
patient survival [52], while Kojima et al. [53] observedno differences in DFS between CD133-positive and-
negative patients, although they considered CD133 over-
expression to be a risk factor in patients with well- and
moderately-differentiated adenocarcinomas. CD133 ex-
pression on cell debris and the endoluminal surface has
also been proposed as CRC biomarker. Horst et al. [29]
found a significant correlation between endoluminal sur-
face CD133 expression and low survival in CRC patients,
while Xi et al. [54] reported that CD133 expression in
membrane and cytoplasm of cells on the luminal surface
of cancerous glands was of prognostic value in CRC pa-
tients. All these results are supported by CD133 mRNA
studies too. Saigusa et al. [55] observed correlation be-
tween CD133 mRNA expression and survival and distant
recurrence in rectal patients. Further, Kawamoto et al.
[56] associated recurrence and short DFS with higher
CD133 RNAm levels. Similar results observed Yasuda
et al. [57].
The comparison of results among studies is hampered
by methodological differences. Thus, CD133 staining
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AC133 (Miltenyi Biotech) and Ab19898 (Abcam) mono-
clonal antibodies [49] and among the application of anti-
CD133 (Cell Signalling), AC133 (Miltenyi Biotech), and
polyclonal anti-CD133 (Santa Cruz Biotechnology) anti-
bodies [29]. These staining variations were confirmed in
previous glioblastoma studies [58]. In addition, whereas
some authors compared cell cytoplasm staining between
patients with less and more than 5% CD133 positive
cells [49,54,59], others compared the number of CD133-
stained glands between patients with less and more than
50% positive glands [29].
Finally, MGMT expression or methylation status has
been related to radio-chemo/resistance in the CSC
population in some tumors such as glioma [24-26]. He
et al. [25] reported that patients with methylated MGMT
promoter and high CD133 expression had the worst
progression-free survival. In contrast, Metellus et al.
[26] observed shorter OS and progression-free survi-
val in patients with unmethylated MGMT and high
CD133 expression. In the present study, no significant
association was found between MGMT and CD133 in
CRC patients. However, consistent with the findings of He
et al. [25], DFS and OS outcomes were worse in patients
with low MGMT expression intensity and ≥50% CD133
expression.Conclusions
Our study evidences the relevance of MGMT and CD133
in the clinical outcome of CRC patients. High MGMT ex-
pression intensity was correlated with longer overall sur-
vival, while high percentage of CD133 expression was
related to shorter-recurrence time lapse. Hence, the inten-
sity of MGMT protein expression and the percentage
CD133 protein expression may help to identify patients
who need a more aggressive adjuvant therapy.Additional files
Additional file 1: Tables S1. Association between molecular variables.
Additional file 2: Tables S2. Association between histopathological
and MGMT molecular variables.
Additional file 3: Tables S3. Association between histopathological
variables and CD133 protein expression.Abbreviations
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